Jasper Therapeutics Reports $18.7 Million Net Loss in Q3 2025 Amid Rising R&D Expenses

Jasper Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $18.7 million, slightly higher than the $18.6 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company experienced a net loss of $66.7 million, compared to a loss of $46.9 million for the same period in the previous year. The increase in losses is attributed to rising research and development expenses, which surged by 44% to $51.7 million for the nine months ended September 30, 2025, primarily due to increased costs associated with clinical trials and personnel-related expenses.

Total operating expenses for the third quarter of 2025 decreased by 4% to $19.2 million, down from $19.9 million in the prior year. This decline was driven by reduced general and administrative costs, which fell by 12% to $4.8 million. However, research and development expenses remained relatively stable, with a slight decrease of $0.1 million compared to the previous year. The company reported a significant increase in accounts payable, which rose to $9.2 million from $4.0 million at the end of 2024, reflecting ongoing operational challenges.

In terms of strategic developments, Jasper Therapeutics implemented a corporate reorganization in July 2025, which included a workforce reduction of approximately 50% to extend its cash runway. This restructuring is expected to help the company focus on its lead product candidate, briquilimab, which is currently in clinical trials for chronic spontaneous urticaria and chronic inducible urticaria. The company also halted enrollment in its Phase 1b/2a asthma study and other clinical programs as part of this strategic shift.

As of September 30, 2025, Jasper Therapeutics had cash and cash equivalents totaling $50.9 million, a decrease from $71.6 million at the end of 2024. The company raised approximately $27.5 million in net proceeds from an underwritten public offering completed in September 2025, which included the issuance of common stock and warrants. Despite this funding, management expressed concerns about the company's ability to continue as a going concern, citing the need for additional financing to support ongoing operations and product development.

Looking ahead, Jasper Therapeutics anticipates continued significant losses as it advances its clinical programs and seeks regulatory approvals. The company plans to finance its future cash needs through a combination of equity or debt financings, collaborations, and other strategic partnerships. However, management acknowledged that the ability to raise additional funds may be adversely impacted by market conditions and other external factors, creating uncertainty regarding the company's financial stability and operational continuity.